临床药师优化颅内感染病人抗感染药物治疗方案的实践
|
摘要
<正>颅内感染是神经外科颅脑术后常见的一种严重并发症。研究发现,颅内感染是多个因素导致的结果,及早采取措施对高危因素病人进行干预,有助于降低颅内感染的病死率[1]。临床药师通过参与病人的药物治疗过程,利用自身药学知识的优势,协助医师制定最优化的药物治疗方案,并实施全程药学服务,在促进抗菌药物合理应用的同时,保证了病人住院期间的用药安全。作者将参与的1例神经外科术后并发颅内感染病人的抗感染治疗实践报道如下。1 病例资料女性,49岁,因"
引文
[1] 邢永国,孟伟英,张淑祥,等.神经外科开颅术后颅内感染诊治新进展[J].中华医院感染学杂志,2016,26(22):5268-5271.XING Yongguo,MENG Weiying,ZHANG Shuxiang,et al.Latest progress of diagnosis and treatment of postoperative intracranial infection in neurosurgery department patients undergoing craniotomy[J].Chin J Nosocomiol,2016,26(22):5268-5271.In Chinese with English abstract.
[2] van de Beek D,Cabellos C,Dzupova O,et al.ESCMID guidelines:diagnosis and treatment of acute bacterial meningitis[J].Clin Microbiol Infect,2016,22(Suppl 3):S37-S62.
[3] 戴维·吉尔伯特.热病:桑德福抗微生物治疗指南[M].范洪伟,译.46版.北京:中国协和医科大学出版社,2017:8-10.Gilbert D N.Hot disease:Sanford anti-microbial treatment guidelines[M].Translated by FAN Hongwei.46 ed.Beijing:China Union Medical University Press,2017:8-10.In Chinese.
[4] YE Zhikang,CHEN Yaolong,CHEN Ken,et al.Therapeutic drug monitoring of vancomycin:a guideline of the division of therapeutic drug monitoring,Chinese pharmacological Society[J].J Antimicrob Chemother,2016,71(11):3020-3025.
[5] 翟所迪,贺蓓,王睿,等.《中国万古霉素治疗药物监测指南》解读[J].中国临床药理学杂志,2016,32(17):1633-1636.ZHAI Suodi,HE Bei,WANG Rui,et al.Expert consensus on the therapeutic drug monitoring of vancomycin in China[J].Chin J Clin Pharmacol,2016,32(17):1633-1636.In Chinese.
[6] 陈佰义,管向东,何礼贤,等.万古霉素临床应用中国专家共识(2011版)[J].中国新药与临床杂志,2011,30(8):561-573.CHEN Baiyi,GUAN Xiangdong,HE Lixian,et al.Expert consensus on the clinical application of vancomycin in China(2011) [J].Chin J New Drugs Clin Rem,2011,30(8):561-573.In Chinese.
[2] van de Beek D,Cabellos C,Dzupova O,et al.ESCMID guidelines:diagnosis and treatment of acute bacterial meningitis[J].Clin Microbiol Infect,2016,22(Suppl 3):S37-S62.
[3] 戴维·吉尔伯特.热病:桑德福抗微生物治疗指南[M].范洪伟,译.46版.北京:中国协和医科大学出版社,2017:8-10.Gilbert D N.Hot disease:Sanford anti-microbial treatment guidelines[M].Translated by FAN Hongwei.46 ed.Beijing:China Union Medical University Press,2017:8-10.In Chinese.
[4] YE Zhikang,CHEN Yaolong,CHEN Ken,et al.Therapeutic drug monitoring of vancomycin:a guideline of the division of therapeutic drug monitoring,Chinese pharmacological Society[J].J Antimicrob Chemother,2016,71(11):3020-3025.
[5] 翟所迪,贺蓓,王睿,等.《中国万古霉素治疗药物监测指南》解读[J].中国临床药理学杂志,2016,32(17):1633-1636.ZHAI Suodi,HE Bei,WANG Rui,et al.Expert consensus on the therapeutic drug monitoring of vancomycin in China[J].Chin J Clin Pharmacol,2016,32(17):1633-1636.In Chinese.
[6] 陈佰义,管向东,何礼贤,等.万古霉素临床应用中国专家共识(2011版)[J].中国新药与临床杂志,2011,30(8):561-573.CHEN Baiyi,GUAN Xiangdong,HE Lixian,et al.Expert consensus on the clinical application of vancomycin in China(2011) [J].Chin J New Drugs Clin Rem,2011,30(8):561-573.In Chinese.